Renal and Extrarenal Phenotypes in Patients With Variants and Chromosome 17q12 Microdeletions
Overview
Authors
Affiliations
Introduction: Hepatocyte nuclear factor 1-beta () gene variants or the chromosome 17q12 deletion (17q12del) represent the most common monogenic cause of developmental kidney disease. Although neurodevelopmental disorders have been associated with the 17q12del, specific genotype-phenotype associations with respect to kidney function evolution have not yet been fully defined. Here, we aimed to determine whether 17q12del or specific variants were associated with kidney survival in a large patient population with disease.
Methods: This was a retrospective observational study involving 521 patients with disease from 14 countries using the European Reference Network for rare kidney diseases with detailed information on the genotype ( variants or the 17q12del). Median follow-up time was 11 years with 6 visits per patient. The primary end point was progression to chronic kidney disease (CKD) stage 3 (estimated glomerular filtration rate [eGFR] < 60 ml/min per 1.73 m). Secondary end points were the development of hypomagnesemia or extrarenal disorders, including hyperuricemia and hyperglycemia.
Results: Progression toward CKD stage 3 was significantly delayed in patients with the 17q12del compared to patients with variants (hazard ratio [HR]: 0.29, 95% confidence interval [CI]: 0.19-0.44, < 0.001). Progression toward CKD stage 3 was also significantly delayed when variants involved the HNF1B Pit-1, Oct-1, and Unc-86 homeodomain (POU) DNA-binding and transactivation domains rather than the POU-specific domain (POU) DNA-binding domain (HR: 0.15 [95% CI: 0.06-0.37), < 0.001 and HR: 0.25 (95% CI: 0.11-0.57), = 0.001, respectively). Finally, the 17q12del was positively associated with hypomagnesemia and negatively associated with hyperuricemia, but not with hyperglycemia.
Conclusion: Patients with the 17q12del display a significantly better kidney survival than patients with other variants; and for the latter, variants in the POU DNA-binding domain lead to the poorest kidney survival. These are clinically relevant kidney genotype-phenotype correlations that inform genetic counseling.
[The European Rare Kidney Disease Reference Network].
Wlodkowski T, Haeberle S, Schaefer F Inn Med (Heidelb). 2024; 65(12):1283-1292.
PMID: 39538006 DOI: 10.1007/s00108-024-01810-3.
Missing in Plain Sight No More? Copy Number Variation in Monogenic Kidney Disease.
Jefferis J, Mallett A Kidney Int Rep. 2024; 9(10):2851-2853.
PMID: 39430168 PMC: 11489509. DOI: 10.1016/j.ekir.2024.08.017.
Transcription Factor: Key Regulator in Renal Physiology and Pathogenesis.
Sanchez-Cazorla E, Carrera N, Garcia-Gonzalez M Int J Mol Sci. 2024; 25(19).
PMID: 39408938 PMC: 11476927. DOI: 10.3390/ijms251910609.